Actavis Generics Overview
- Year Founded
-
1956
- Status
-
Acquired/Merged
- Employees
-
25,000
- Latest Deal Type
-
M&A
- Financing Rounds
-
3
- Investments
-
15
Actavis Generics General Information
Description
Provider of generic pharmaceutical products. The company provides generic pharmaceutical products for human use covering alimentary tract and metabolism, cardiovascular system, central nervous system, genito-urinary and sex hormones, anti-infective, musculo-skeletal system, oncology, respiratory system and dermatological therapeutic categories.
Contact Information
Website
www.actavis.comCorporate Office
- Turmstrasse 24
- 6300 Zug
- Switzerland
Corporate Office
- Turmstrasse 24
- 6300 Zug
- Switzerland
Actavis Generics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Actavis Generics Comparisons
Industry
Financing
Details
Actavis Generics Competitors (13)
One of Actavis Generics’s 13 competitors is H. Lundbeck, a Corporation company based in Copenhagen, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| H. Lundbeck | Corporation | Copenhagen, Denmark | ||||
| Tris Pharma | Private Debt Financed | Monmouth Junction, NJ | ||||
| Bluefish Pharmaceuticals | Private Equity-Backed | Stockholm, Sweden | ||||
| Alvogen Group | Formerly PE-Backed | Morristown, NJ | ||||
| MS Pharma | Private Equity-Backed | Amman, Jordan |
Actavis Generics Patents
Actavis Generics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2018148361-A1 | Process for the preparation of remimazolam and solid state forms of remimazolam salts | Inactive | 09-Feb-2017 | ||
| US-10993943-B2 | Crystalline forms of selinexor and process for their preparation | Inactive | 05-Jan-2017 | ||
| EP-3565813-A1 | Novel crystalline forms of selinexor and process for their preparation | Inactive | 05-Jan-2017 | ||
| US-20190336499-A1 | Novel crystalline forms of selinexor and process for their preparation | Active | 05-Jan-2017 | ||
| US-20210244729-A1 | Novel crystalline forms of selinexor and process for their preparation | Inactive | 05-Jan-2017 | A61K31/497 |
Actavis Generics Signals
Actavis Generics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Actavis Generics Investments & Acquisitions (15)
Actavis Generics’s most recent deal was a Buyout/LBO with PharmaPack International. The deal was made on 02-Dec-2011.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| PharmaPack International | 02-Dec-2011 | Buyout/LBO | Other Pharmaceuticals and Biotechnology | ||
| Specifar Pharmaceuticals | 25-May-2011 | Merger/Acquisition | Pharmaceuticals | ||
| M8 Pharmaceuticals | 14-Oct-2010 | Later Stage VC | Distributors (Healthcare) | ||
| Pfizer (Nerviano Manufacturing Site) | 28-Jan-2008 | Buyout/LBO | Buildings and Property | ||
| Abrika Pharmaceuticals | 23-Apr-2007 | Merger/Acquisition | Drug Delivery |
Actavis Generics Exits (9)
Actavis Generics’s most recent exit was on 14-Oct-2010 from M8 Pharmaceuticals. The exit was categorized as with 5 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| M8 Pharmaceuticals | 14-Oct-2010 | Completed |
|
||
| ZAO ZiO-Zdorovye | 20-Nov-2006 | Completed |
|
||
| Higia | 09-Dec-2005 | Completed |
|
||
| Actavis Foshan Pharmaceutical | 01-Jan-2005 | Completed |
|
||
| Foshan Chiral Pharmaceutical | 01-Jan-2005 | Merger/Acquisition | Completed |
Actavis Generics FAQs
-
When was Actavis Generics founded?
Actavis Generics was founded in 1956.
-
Where is Actavis Generics headquartered?
Actavis Generics is headquartered in Zug, Switzerland.
-
What is the size of Actavis Generics?
Actavis Generics has 25,000 total employees.
-
What industry is Actavis Generics in?
Actavis Generics’s primary industry is Pharmaceuticals.
-
Is Actavis Generics a private or public company?
Actavis Generics is a Private company.
-
What is the current valuation of Actavis Generics?
The current valuation of Actavis Generics is .
-
What is Actavis Generics’s current revenue?
The current revenue for Actavis Generics is .
-
Who are Actavis Generics’s investors?
ALMC, Allergan, Landsbankinn, and Novator Partners have invested in Actavis Generics.
-
Who are Actavis Generics’s competitors?
H. Lundbeck, Tris Pharma, Bluefish Pharmaceuticals, Alvogen Group, and MS Pharma are some of the 13 competitors of Actavis Generics.
-
When was Actavis Generics acquired?
Actavis Generics was acquired on 01-Jul-2016.
-
Who acquired Actavis Generics?
Actavis Generics was acquired by Teva Pharmaceutical Industries.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process